Sacituzumab Govitecan for metastatic cancer, New Delhi

Sacituzumab Govitecan is a groundbreaking antibody-drug conjugate (ADC) designed to target cancer cells with remarkable precision while minimizing damage to healthy tissues. Its innovative composition combines an anti-Trop-2 monoclonal antibody with SN-38, an active metabolite of irinotecan, thereby delivering potent anticancer activity directly to tumor cells. One of the major benefits of Sacituzumab Govitecan is its ability to specifically target cancer cells, reducing the risk of damage to healthy cells and minimizing side effects.Sacituzumab Govitecan 180 Mg in India stands as a beacon of innovation in cancer treatment, offering newfound hope and efficacy for Cancer patients.